These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8692305)

  • 21. Development of a faecal occult blood test to determine the severity of Haemonchus contortus infections in sheep.
    Colditz IG; Le Jambre LF
    Vet Parasitol; 2008 May; 153(1-2):93-9. PubMed ID: 18299173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of a positive fecal occult blood test increases as the severity of CKD worsens.
    Bini EJ; Kinkhabwala A; Goldfarb DS
    Am J Kidney Dis; 2006 Oct; 48(4):580-6. PubMed ID: 16997054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diagnostic methods in gastroenterology in the physician's office].
    Malè PJ; Borst F; de Peyer R; Meyer P
    Ther Umsch; 1988 Aug; 45(8):553-8. PubMed ID: 3051506
    [No Abstract]   [Full Text] [Related]  

  • 24. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests.
    Levin B; Hess K; Johnson C
    Arch Intern Med; 1997 May; 157(9):970-6. PubMed ID: 9140267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of diverticulosis coli and vascular ectasias and the results of fecal occult blood test.
    Nakama H; Fattah AS; Zhang B; Kamijo N; Uehara Y
    Hepatogastroenterology; 2000; 47(35):1277-9. PubMed ID: 11100332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in diagnosing lower gastrointestinal disorders.
    Health Devices; 1994 May; 23(5):152-3. PubMed ID: 10147157
    [No Abstract]   [Full Text] [Related]  

  • 27. Relationship between the fecal occult blood test and benign anal disorders.
    Sasaki K; Kunimoto M; Hirata K
    Hepatogastroenterology; 2001; 48(38):445-7. PubMed ID: 11379329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colorectal cancer screening through detection of fecal occult blood in a controlled health zone.
    Tárraga P; García-Olmo D; Celada A; García-Molinero Mf; Divison JA; Casado C
    Rev Esp Enferm Dig; 1999 May; 91(5):335-44. PubMed ID: 10362875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population colorectal cancer screening with fecal occult blood test.
    Rennert G; Rennert HS; Miron E; Peterburg Y
    Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1165-8. PubMed ID: 11700264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colorectal cancer risk in first-degree relatives of patients with colorectal adenomatous polyp.
    Nakama H; Fukazawa K
    Hepatogastroenterology; 2002; 49(43):157-9. PubMed ID: 11941942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Quantitative determination of blood loss from the gastrointestinal tract using Metol in chronic diseases of the digestive organs].
    Kanishchev PA; Bereza NM; Seniuk VF; Perevziaka AV
    Lab Delo; 1989; (3):36-8. PubMed ID: 2469837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laboratory evaluation of the gastrointestinal tract.
    Goldston RT; Seybold IM; Wilkes RD
    Vet Med Small Anim Clin; 1982 Jan; 77(1):31-4. PubMed ID: 6917615
    [No Abstract]   [Full Text] [Related]  

  • 33. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
    Sharma VK; Corder FA; Fancher J; Howden CW
    Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled trial of a clinic-based support staff intervention to increase the rate of fecal occult blood test ordering.
    Thompson NJ; Boyko EJ; Dominitz JA; Belcher DW; Chesebro BB; Stephens LM; Chapko MK
    Prev Med; 2000 Mar; 30(3):244-51. PubMed ID: 10684748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods.
    Yamamoto M; Nakama H
    Hepatogastroenterology; 2000; 47(32):396-9. PubMed ID: 10791199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Occult blood in the stool.
    WILCOX HR
    Nebr State Med J; 1956 May; 41(5):176-9. PubMed ID: 13309436
    [No Abstract]   [Full Text] [Related]  

  • 39. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fecal occult blood testing: clinical value and limitations.
    Simon JB
    Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.